| Natural compounds for cancer treatment and prevention S Nobili, D Lippi, E Witort, M Donnini, L Bausi, E Mini, S Capaccioli Pharmacological research 59 (6), 365-378, 2009 | 995 | 2009 |
| Cellular pharmacology of gemcitabine E Mini, S Nobili, B Caciagli, I Landini, T Mazzei Annals of oncology 17, v7-v12, 2006 | 956 | 2006 |
| Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ... Journal of Clinical Oncology 27 (19), 3117-3125, 2009 | 606 | 2009 |
| Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies S Nobili, E Mini, I Landini, C Gabbiani, A Casini, L Messori Medicinal research reviews 30 (3), 550-580, 2010 | 583 | 2010 |
| Pharmacokinetic drug interactions of macrolides P Periti, T Mazzei, E Mini, A Novelli Clinical pharmacokinetics 23, 106-131, 1992 | 492 | 1992 |
| Gold (III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold (III) compounds L Messori, F Abbate, G Marcon, P Orioli, M Fontani, E Mini, T Mazzei, ... Journal of medicinal chemistry 43 (19), 3541-3548, 2000 | 450 | 2000 |
| Pharmacological strategies for overcoming multidrug resistance S Nobili, I Landini, B Giglioni, E Mini Current drug targets 7 (7), 861-879, 2006 | 443 | 2006 |
| Gold (III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties G Marcon, S Carotti, M Coronnello, L Messori, E Mini, P Orioli, T Mazzei, ... Journal of Medicinal Chemistry 45 (8), 1672-1677, 2002 | 349 | 2002 |
| Structure, expression, and regulation of protein kinases involved in the phosphorylation of ribosomal protein S6 RL Erikson The Journal of biological chemistry 266 (10), 6007-6010, 1991 | 330 | 1991 |
| Gold (III) compounds as anticancer agents: Relevance of gold–protein interactions for their mechanism of action A Casini, C Hartinger, C Gabbiani, E Mini, PJ Dyson, BK Keppler, ... Journal of inorganic biochemistry 102 (3), 564-575, 2008 | 324 | 2008 |
| Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial J Taieb, J Tabernero, E Mini, F Subtil, G Folprecht, JL Van Laethem, ... The Lancet Oncology 15 (8), 862-873, 2014 | 310 | 2014 |
| Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer J Taieb, K Le Malicot, Q Shi, F Penault-Llorca, O Bouché, J Tabernero, ... Journal of the National Cancer Institute 109 (5), djw272, 2017 | 305 | 2017 |
| A novel inward‐rectifying K+ current with a cell‐cycle dependence governs the resting potential of mammalian neuroblastoma cells. A Arcangeli, L Bianchi, A Becchetti, L Faravelli, M Coronnello, E Mini, ... The Journal of Physiology 489 (2), 455-471, 1995 | 299 | 1995 |
| Chemistry and mode of action of macrolides T Mazzei, E Mini, A Novelli, P Periti Journal of antimicrobial chemotherapy 31 (suppl_C), 1-9, 1993 | 291 | 1993 |
| High-Resolution Melting Analysis for Rapid Detection of KRAS, BRAF, and PIK3CA Gene Mutations in Colorectal Cancer L Simi, N Pratesi, M Vignoli, R Sestini, F Cianchi, R Valanzano, S Nobili, ... American journal of clinical pathology 130 (2), 247-253, 2008 | 277 | 2008 |
| Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold (III) compounds with bipyridyl ligands A Casini, MA Cinellu, G Minghetti, C Gabbiani, M Coronnello, E Mini, ... Journal of Medicinal Chemistry 49 (18), 5524-5531, 2006 | 241 | 2006 |
| Adverse effects of macrolide antibacterials P Periti, T Mazzei, E Mini, A Novelli Drug safety 9, 346-364, 1993 | 228 | 1993 |
| Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum S Capaccioli, G Dipasquale, E Mini, T Mazzei, A Quattrone Biochemical and biophysical research communications 197 (2), 818-825, 1993 | 227 | 1993 |
| Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. DE McCloskey, JJ McGuire, CA Russell, BG Rowan, JR Bertino, ... Journal of Biological Chemistry 266 (10), 6181-6187, 1991 | 217 | 1991 |
| Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression S Nobili, I Landini, T Mazzei, E Mini Medicinal research reviews 32 (6), 1220-1262, 2012 | 211 | 2012 |
